- Craneware saw continued growth in the six months to the end of December and expects to report 15% increases in both revenue and adjusted EBITDA.

It says this builds on the return to double digit growth reported in the year to 30 June and is slightly ahead of expectations.

Underlying sales continue to support this growth, with a particularly strong Q2, post the US election result, and a healthy sales pipeline.

In accordance with the company's revenue recognition policy the vast majority of revenue resulting from sales made in the period will be recognised over future periods, adding to the group's long term visibility of revenue under contract.

Chief executive Keith Neilson said: "There is continued consensus in the US of the need to drive value in Healthcare with ongoing support for the move to value-based care and increasing consumerism. An impending change of government always brings with it an element of uncertainty, it was therefore particularly pleasing to see the acceleration in sales of our Value Cycle solutions post the result of the US presidential election.

"Our Value Cycle software continues to help US Healthcare providers meet the challenges they will face as they navigate the ongoing re-imbursement model changes. "We continue to invest in both our current solutions and in the new products we are developing to expand our support to US Healthcare providers as they pursue quality patient outcomes and optimal financial performance. "These supportive market drivers, our investment for the future and our continued profitable growth, give management confidence in its ability to deliver continued stakeholder value."

At 8:10am: [LON:CRW] Craneware PLC share price was +80p at 1365p

Story provided by